Andere talen Olema Pharmaceuticals, Inc.

Aandelen

OLMA

US68062P1066

Geschatte realtime Cboe BZX Andere beurzen 20:42:22 24-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
10,05 ^USD	+0,50%		-6,35%	-28,51%

02/04	OLEMA PHARMACEUTICALS, INC. : Goldman Sachs stelt koopadvies voor	ZM
12/03	OLEMA PHARMACEUTICALS, INC. : HC Wainwright nog altijd een koopadvies	ZM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference	08/04
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	02/04
Olema Pharmaceuticals, Inc.(NasdaqGS:OLMA) added to S&P Biotechnology Select Industry Index	18/03
Olema Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	11/03
Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update	11/03
Olema Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	11/03
Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors	06/03
Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors	06/03
Olema Oncology Announces Publication of Data Highlighting Palazestrant?s Ability to Inhibit Wild-Type and Mutant Er+ Breast Cancer Both as Monotherapy and in Combination with Cdk4/6 Inhibitors	06/03
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	04/03
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	04/03
Olema Oncology to Participate in Upcoming Investor Conferences	06/02
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	02/02
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	02/02
Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate	08/01
Olema Pharmaceuticals, Inc. Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate	08/01
Olema Oncology to Present at 42nd Annual J.P. Morgan Healthcare Conference	02/01
Olema Pharmaceuticals, Inc.(NasdaqGS:OLMA) added to NASDAQ Biotechnology Index	18/12
Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies	05/12
Olema Pharmaceuticals, Inc. Announces Palazestrant Demonstrates Attractive Combinability with Cdk4/6 Inhibitors Ribociclib and Palbociclib in Phase 1B/2 Studies	05/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Olema Pharmaceuticals, Inc.

Aandelen

OLMA

US68062P1066

Andere talen

Filters